Agouron and the Immune Response Corporation to Collaborate on Commercialization of Remune(TM) [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

Agouron and The Immune Response Corporation to Collaborate on Commercialization of
REMLNETM
June 11, 1998
Page 2
Given the intense recent interest in REMUNE on the part of companies committed to the field of
HIV therapy, we are very gratified that Agouron has been selected by Immune Response as its
commercial partner for major markets."
"We welcome this collaboration with one of the world leaders in the treatment of HIV.
Agouron's experienced development and marketing team will be invaluable when we transition
our focus from the development of REMUNE to making it commercially available to those infected
with HIV," said Dennis J. Carlo, Ph.D., president and chief executive officer of Immune
Response.
An important recent goal in treatment of HIV infection is to combine such highly active
drugs as HIV protease inhibitors, capable of halting replication of HIV, with agents capable of
directly enhancing recovery of the immune system. As part of the collaboration, Agouron will
sponsor a new surrogate marker trial of REMUNE taken in combination with highly active drug
regimens containing Agouron's marketed protease inhibitor VIRACEPT~ (nelfinavir mesylate).
REMUNE is an immune-based therapy, derived from HIV itself, which has been shown to
elicit an HIV-specific immune response. In May 1997, enrollment was completed at 74 centers in
the United States for a pivotal phase III, clinical endpoint trial in which approximately 2500
patients were randomized to receive conventional antiretroviral drug therapy with or without
REMUNE administered as an intramuscular injection every three months. This trial is expected to
be complete in April 1999. More than 300 patients have been enrolled in two other clinical studies
which are evaluating the effect of REMUNE in combination with antiretroviral drugs on virologic
and immunologic markers in adults. A smaller study of REMUNE for treatment of HIV infection
in children is in progress at the National Institutes of Health.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad,
California, developing immune-based therapies to induce specific T-cell responses for the
treatment of HIV, autoimmune diseases and cancer. The company is conducting clinical trials for
its immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon
cancer and brain cancer and preclinical studies for melanoma and prostate cancers. In addition,
the company is developing a targeted delivery technology for gene therapy which is designed to
enable the intravenous injection of genes for delivery directly to the liver. The company's gene
therapy program is currently focused on diseases of the liver and is in preclinical studies for the

treatment of hemophilia and hepatitis.
-more